Datametrex AI (TSXV: DM) announced this morning that it has entered into a strategic partnership and development agreement with Transpharm Canada, a full serivce clinical development operation and North America’s premier pharmaceutical training institute.
Under the partnership agreement, Transpharm is to work with Datametrex to provide support and testing services for COVID-19 testing kits that are in Datametrex’s portfolio. The company will also assist in scoping out related services, which includes specimen collection, transportation, and processing of test results.
Furthermore, Transpharm will design and develop a fully integrated suite of testing systems that include field and lab testing protocols. Testing will be conducted at the firms GMP certified lab in Toronto, Ontario, which has the current capacity to process 2,304 nucleic acid COVID-19 detection kits every 24 hours. The facility currently has the ability to scale the testing operation to over 10,000 test kits every 24 hours should the demand exist.
Datametrex currently has relationships with four South Korean manufacturers of nucleic acid coronavirus test kits. Given that both public and private corporations are not yet fully equipped to administer and process test kits on their own, the company sought its own solution to the problem by finding Transpharm as their lab partner.
Datametrex AI last traded at $0.12 on the TSX Venture.
Information for this briefing was found via Sedar and Datametrex AI. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
